Effect of continuous oral diethylcarbamazine treatment on lymphocyte counts of feline leukemia virus-infected cats.
In previous studies, administration of diethylcarbamazine (DEC) resulted in increased serum antibody titers to feline oncornavirus-associated cell membrane antigen (FOCMA) in cats infected with feline leukemia virus (FeLV). FeLV infection of cats frequently results in immunosuppression associated with lymphopenia. The present investigation demonstrated that chronic administration of DEC prevented or delayed severe lymphopenia in two FeLV-infected offspring of an FeLV-infected queen as compared to two untreated littermates.
Kitchen
L W
LW
Department of Cancer Biology, Harvard School of Public Health, Boston, MA 02115.
Mather
F J
FJ
Cotter
S M
SM
D000818:Animals; D000831:Animals, Newborn; D000956:Antigens, Viral / Q000032:analysis; D002371:Cat Diseases / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D002415:Cats; D004049:Diethylcarbamazine / Q000008:administration & dosage*; D005260:Female; D007938:Leukemia / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D005256:Leukemia Virus, Feline / Q000276:immunology; D007958:Leukocyte Count; D008231:Lymphopenia / Q000517:prevention & control; D008297:Male; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*
D000956:Antigens, Viral; D004049:Diethylcarbamazine